Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
26/01/2026 13:07
Jan 26 (Reuters) - Sarepta Therapeutics' SRPT.O gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data from a late‑stage study released on Monday. (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure